This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moorehead, M. T. Articles by Bull, B. S. Search for Related Content PubMed PubMed Citation Articles by Moorehead, M. T. Articles by Bull, B. S.

Platelet Involvement in the Activated Coagulation Time of Heparinized Blood

The Department of Pathology and Laboratory Medicine, Loma Linda University Medical Center.

Abstract

The activated coagulation time (ACT), commonly used during cardiopulmonary bypass (CPB), is assumed to measure only differences in heparin levels. Studies were undertaken to determine whether platelet activation/inhibition might also influence the test. When either the platelet inhibitor prostacyclin or the platelet activator adenosine diphosphate (ADP) was added to healthy donor blood containing 2 1U of heparin per ml, there was significant prolongation of the ACT (prostacyclin: mean prolongation, 60.6%; ADP: mean prolongation, 52.3%). In blood taken from the extracorporeal circuit of ten CPB cases, the prolongation with the platelet inhibitor carbacyclin, a prostacyclin analogue, was infinite. It is concluded that the ACT as used during CPB must be interpreted as a measure of both platelet procoagulant activity and heparin activity. Furthermore, this dual sensitivity, while fortuitous, is probably advantageous; patients with hyporeactive platelets will automatically receive less heparin.

Key Words: BLOOD—coagulation. • ANESTHESIA—cardiovascular. • SURGERY—cardiovascular.

This article has been cited by other articles:

				N. A. Guzzetta, B. E. Miller, K. Todd, F. Szlam, R. H. Moore, K. K. Brosius, E. C. Wilson, A. M. Cohen, and S. R. Tosone Clinical Measures of Heparin's Effect and Thrombin Inhibitor Levels in Pediatric Patients with Congenital Heart Disease Anesth. Analg., November 1, 2006; 103(5): 1131 - 1138. [Abstract] [Full Text] [PDF]

				P. Federico, F. Annalisa, C. Giuseppe, D. S. Francesco, T. Lucia, and Z. Alberto Anticoagulation management in patients undergoing open heart surgery by activated clotting time and whole blood heparin concentration Perfusion, September 1, 2006; 21(5): 285 - 290. [Abstract] [PDF]

				M. T. Ganter, A. Monn, R. Tavakoli, M. Genoni, R. Klaghofer, L. Furrer, H. Honegger, and C. K. Hofer Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot. Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 278 - 284. [Abstract] [Full Text] [PDF]

				M. Mittermayr, J. Margreiter, C. Velik-Salchner, A. Klingler, W. Streif, D. Fries, and P. Innerhofer Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem(R)): an in vitro study Br. J. Anaesth., September 1, 2005; 95(3): 310 - 316. [Abstract] [Full Text] [PDF]

				M. T. Ganter, S. Dalbert, K. Graves, R. Klaghofer, A. Zollinger, and C. K. Hofer Monitoring Activated Clotting Time for Combined Heparin and Aprotinin Application: An In Vitro Evaluation of a New Aprotinin-Insensitive Test Using SONOCLOT Anesth. Analg., August 1, 2005; 101(2): 308 - 314. [Abstract] [Full Text] [PDF]

				S Svenmarker, M Appelblad, E Jansson, and S Haggmark Measurement of the activated clotting time during cardiopulmonary bypass: differences between Hemotec(R) ACT and Hemochron(R) Jr apparatus Perfusion, September 1, 2004; 19(5): 289 - 294. [Abstract] [PDF]

				K. A. Tanaka, N. Katori, F. Szlam, N. Sato, A. B. Kelly, and J. H. Levy Effects of tirofiban on haemostatic activation in vitro Br. J. Anaesth., August 1, 2004; 93(2): 263 - 269. [Abstract] [Full Text] [PDF]

				M. Wallock, W. P Jeske, M. Bakhos, and J. M Walenga Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test Perfusion, March 1, 2001; 16(2): 147 - 153. [Abstract] [PDF]

				C Gruenwald, V de Souza, A K. Chan, and M Andrew Whole blood heparin concentrations do not correlate with plasma antifactor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass Perfusion, May 1, 2000; 15(3): 203 - 209. [Abstract] [PDF]

				L. Shore-Lesserson, H. E. Manspeizer, M. Bolastig, D. Harrington, F. Vela-Cantos, and M. DePerio Anticoagulation for Cardiac Surgery in Patients Receiving Preoperative Heparin: Use of the High-Dose Thrombin Time Anesth. Analg., April 1, 2000; 90(4): 813 - 818. [Abstract] [Full Text] [PDF]

				J. Himber, L. Burcklen, and B. Steiner Effects of GP IIb/IIIa receptor antagonists on the activated clotting time of heparinized blood Blood, March 15, 2000; 95(6): 2189 - 2190. [Full Text] [PDF]

				R. F Baugh Platelets and whole blood coagulation Perfusion, January 1, 2000; 15(1): 41 - 50. [Abstract] [PDF]

				H. I. Flom-Halvorsen, E. Ovrum, M. Abdelnoor, S. Bjornsen, and F. Brosstad Assessment of heparin anticoagulation: comparison of two commercially available methods Ann. Thorac. Surg., April 1, 1999; 67(4): 1012 - 1016. [Abstract] [Full Text] [PDF]

				D. Royston Hemostatic Drugs in Prothrombotic or Hypercoagulable States Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 376 - 394. [Abstract] [PDF]

				T. Ammar, L. E. Scudder, and B. S. Coller In Vitro Effects of the Platelet Glycoprotein IIb/IIIa Receptor Antagonist c7E3 Fab on the Activated Clotting Time Circulation, February 4, 1997; 95(3): 614 - 617. [Abstract] [Full Text]

				J.-F. Hardy, S. Belisle, D. Robitaille, J. Perrault, M. Roy, and L. Gagnon MEASUREMENT OF HEPARIN CONCENTRATION IN WHOLE BLOOD WITH THE HEPCON/HMS DEVICE DOES NOT AGREE WITH LABORATORY DETERMINATION OF PLASMA HEPARIN CONCENTRATION USING A CHROMOGENIC SUBSTRATE FOR ACTIVATED FACTOR X J. Thorac. Cardiovasc. Surg., July 1, 1996; 112(1): 154 - 161. [Abstract] [Full Text]

				G. J. Despotis, S. A. Santoro, E. Spitznagel, K. M. Kater, J. L. Cox, P. Barnes, and D. G. Lappas Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation J. Thorac. Cardiovasc. Surg., January 1, 1994; 107(1): 271 - 279. [Abstract] [Full Text]